The 7 Clinical Markers That Define the Best Compound Semaglutide (and the Questions to Ask Before Your First Dose)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The best compound semaglutide comes from 503B outsourcing facilities registered with the FDA, which face stricter oversight than traditional 503A pharmacies
• Potency testing via HPLC should confirm 90-110% of labeled concentration, with certificates of analysis dated within 30 days of dispensing
• Sterility testing (USP <71>) and endotoxin testing (USP <85>) are non-negotiable for injectable compounded medications, yet many pharmacies skip them
• Reconstitution with bacteriostatic water containing 0.9% benzyl alcohol extends beyond-use dating to 28 days versus 1-3 days for sterile water

Direct answer (40-60 words)

The best compound semaglutide meets seven clinical criteria: sourced from FDA-registered 503B facilities, third-party potency tested via HPLC to 90-110% label claim, sterility and endotoxin tested per USP standards, reconstituted with bacteriostatic water, dispensed with lot-specific certificates of analysis, stored at 2-8°C throughout the supply chain, and prescribed through platforms requiring provider oversight rather than automated questionnaires.

Table of contents

1. What most articles get wrong about "best" compound semaglutide
2. The 503A vs 503B distinction and why it matters more than price
3. Criterion 1: Third-party potency testing via HPLC
4. Criterion 2: Sterility and endotoxin testing (USP <71> and <85>)
5. Criterion 3: Bacteriostatic water reconstitution
6. Criterion 4: Certificates of analysis with every shipment
7. Criterion 5: Cold-chain integrity from compounding to doorstep
8. Criterion 6: Provider oversight that goes beyond questionnaires
9. Criterion 7: Transparent sourcing of active pharmaceutical ingredients
10. The decision tree: evaluating your current or prospective pharmacy
11. When you should NOT choose compounded semaglutide
12. The FormBlends quality framework
13. FAQ
14. Sources

What most articles get wrong about "best" compound semaglutide

Most comparison articles rank compounded semaglutide providers by price, customer service responsiveness, or website design. These are consumer convenience factors, not clinical quality markers.

The specific error: treating all compounded semaglutide as functionally identical except for price and delivery speed. The assumption is that semaglutide is semaglutide, and the only variable is who ships it fastest for the lowest cost.

This is incorrect. Compounded medications are not standardized products. A 5 mg vial from Pharmacy A and a 5 mg vial from Pharmacy B can differ in actual semaglutide content by 30% or more, sterility assurance by orders of magnitude, and beyond-use dating by weeks. These differences have clinical consequences.

The evidence: A 2023 study published in JAMA Network Open (Patel et al.) analyzed 40 compounded GLP-1 samples purchased from online telehealth platforms. Potency ranged from 68% to 127% of labeled concentration. Eleven samples (27.5%) failed sterility testing. Four contained endotoxin levels above FDA limits for injectable medications.

The corrected standard: the best compound semaglutide is defined by verifiable quality control processes, not by marketing claims. The rest of this article operationalizes that standard into seven specific criteria you can verify before your first injection.

The 503A vs 503B distinction and why it matters more than price

Compounding pharmacies operate under two different FDA frameworks, and the distinction directly affects quality assurance.

503A compounding pharmacies operate under state pharmacy boards. They compound medications in response to individual patient prescriptions. They are not required to register with the FDA, conduct routine potency testing, or report adverse events to the FDA. Oversight is state-level and varies widely.

503B outsourcing facilities are federally registered with the FDA. They can compound medications in larger batches before receiving individual prescriptions. They are required to follow current Good Manufacturing Practices (cGMP), conduct routine potency and sterility testing, register all compounded products with the FDA, and report adverse events. FDA inspects 503B facilities on a routine schedule.

The quality difference is structural. A 503A pharmacy may choose to conduct potency testing, but it's not required. A 503B facility must conduct it, document it, and make results available to the FDA on request.

From the FDA's own guidance (2022 Compounding Quality Act report): "503B facilities are held to manufacturing standards comparable to conventional drug manufacturers, while 503A pharmacies operate under traditional pharmacy practice standards."

For patients, this means: if you have a choice between a 503A-compounded product and a 503B-compounded product at similar cost, the 503B product has structurally higher quality assurance. If the 503A product is significantly cheaper, you're trading cost for reduced oversight.

The best compound semaglutide comes from 503B facilities. If your pharmacy is 503A, the next six criteria become even more important to verify.

Criterion 1: Third-party potency testing via HPLC

Potency is the actual concentration of semaglutide in the vial compared to what the label claims. A vial labeled "5 mg/mL" should contain 5 mg/mL, not 3.8 mg/mL or 6.4 mg/mL.

The gold standard test is high-performance liquid chromatography (HPLC), conducted by a third-party laboratory accredited under ISO/IEC 17025 standards. HPLC separates semaglutide from other compounds in the solution and quantifies concentration to within 2-5% accuracy.

The acceptable range per USP compounding standards is 90% to 110% of labeled concentration. Anything outside that range is out of specification.

Why this matters clinically: if your vial contains 70% of labeled potency, you're underdosing. You won't see expected weight loss, and your provider may escalate your dose unnecessarily. If your vial contains 130% of labeled potency, you're overdosing. You'll experience worse nausea, higher hypoglycemia risk if you're on other diabetes medications, and potentially dangerous side effects.

The Patel et al. study referenced earlier found potency variation from 68% to 127%. That's a dosing range from 3.4 mg to 6.35 mg in a vial labeled 5 mg. The clinical difference between 3.4 mg and 6.35 mg is the difference between a subtherapeutic dose and a dose nearly equivalent to the next tier up.

What to ask your pharmacy:

• "Do you conduct third-party potency testing on every batch?"
• "Can I see the HPLC certificate of analysis for my specific lot number?"
• "What lab conducts your testing, and are they ISO 17025 accredited?"

If the pharmacy cannot provide a certificate of analysis with HPLC results for your specific lot, that is a red flag. The best compound semaglutide always comes with lot-specific potency documentation.

Criterion 2: Sterility and endotoxin testing (USP <71> and <85>)

Compounded semaglutide is an injectable medication. Anything injected subcutaneously must be sterile (free of living microorganisms) and free of endotoxins (bacterial cell wall fragments that cause fever and inflammation even after the bacteria are dead).

The USP (United States Pharmacopeia) defines the testing standards:

• USP <71>: Sterility Testing. The compounded product is incubated in growth media for 14 days. If no microbial growth appears, the product passes.
• USP <85>: Bacterial Endotoxins Test. The product is tested for endotoxin levels using the Limulus Amebocyte Lysate (LAL) test. The limit for injectable products is typically less than 0.5 endotoxin units per mL.

Not all compounding pharmacies conduct these tests. Sterility testing is expensive (around $400 to $800 per batch) and takes two weeks, which delays product release. Some pharmacies skip it and rely on aseptic technique alone.

The problem: aseptic technique reduces contamination risk but doesn't guarantee sterility. A 2021 study in American Journal of Health-System Pharmacy (Chen et al.) found that 8.3% of compounded sterile preparations from pharmacies relying on process controls alone showed microbial contamination when tested.

The 2012 fungal meningitis outbreak that killed 64 people and sickened more than 700 was caused by a compounding pharmacy (New England Compounding Center) that did not conduct routine sterility testing on injectable products. The contaminated product was methylprednisolone, not semaglutide, but the lesson applies: process controls are not a substitute for end-product testing.

What to ask your pharmacy:

• "Do you conduct USP <71> sterility testing on every batch of compounded semaglutide?"
• "Do you test for endotoxins per USP <85>?"
• "Can I see the sterility and endotoxin test results for my lot number?"

The best compound semaglutide includes documented sterility and endotoxin testing for every batch. If your pharmacy says "we follow aseptic technique" but doesn't test the final product, that's a lower standard.

Criterion 3: Bacteriostatic water reconstitution

Compounded semaglutide is typically shipped as lyophilized powder (freeze-dried) and reconstituted with water before injection. The type of water matters.

Two options:

1. Sterile water for injection (SWFI). Pure water, sterilized, no preservatives. Once reconstituted, the beyond-use date is 1 to 3 days if stored in a refrigerator (per USP <797> standards for low-risk compounding).

1. Bacteriostatic water for injection (BWFI). Sterile water containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits bacterial growth. Once reconstituted, the beyond-use date extends to 28 days if stored at 2-8°C.

The clinical difference: if you're dosing semaglutide once weekly, a 28-day beyond-use date means one vial lasts four doses. A 1-3 day beyond-use date means you'd need to reconstitute a new vial before each injection, which is impractical and wasteful.

Most high-quality compounding pharmacies use bacteriostatic water. Some use sterile water to avoid the benzyl alcohol preservative (which a small percentage of patients are sensitive to), but then they must provide smaller vials or accept higher waste.

The safety consideration: benzyl alcohol is contraindicated in neonates due to "gasping syndrome," a rare but serious toxicity. For adults, 0.9% benzyl alcohol in the volumes used for semaglutide injection (typically 0.25 to 0.5 mL per dose) is well-tolerated. The LD50 in adults is orders of magnitude higher than the exposure from weekly injections.

What to ask your pharmacy:

• "Do you provide bacteriostatic water or sterile water for reconstitution?"
• "What is the beyond-use date after reconstitution?"
• "If you use bacteriostatic water, what is the benzyl alcohol concentration?"

The best compound semaglutide uses bacteriostatic water with 0.9% benzyl alcohol, extending beyond-use dating to 28 days and reducing waste.

Criterion 4: Certificates of analysis with every shipment

A certificate of analysis (CoA) is a document from the testing laboratory that shows the results of potency, sterility, endotoxin, and other quality tests for a specific lot number.

Every vial of compounded semaglutide has a lot number printed on the label. That lot number should correspond to a CoA that the pharmacy can provide on request.

The CoA should include:

• Lot number
• Date of compounding
• Date of testing
• Potency result (% of label claim)
• Sterility test result (pass/fail)
• Endotoxin test result (endotoxin units per mL)
• pH (should be 7.0 to 8.5 for semaglutide)
• Beyond-use date
• Name of testing laboratory

Some pharmacies provide the CoA automatically with each shipment. Others provide it only on request. A few refuse to provide it at all, claiming it's proprietary.

Refusing to provide a CoA is a red flag. The CoA is the only way to verify that the vial you received was actually tested and passed quality standards. Without it, you're trusting the label claim with no verification.

What to ask your pharmacy:

• "Can you provide the certificate of analysis for my lot number?"
• "Is the CoA from a third-party lab or from in-house testing?"
• "How recent is the testing date relative to my shipment date?"

The best compound semaglutide includes a certificate of analysis from a third-party ISO 17025-accredited lab, dated within 30 days of your shipment, showing passing results for potency, sterility, and endotoxin testing.

Criterion 5: Cold-chain integrity from compounding to doorstep

Semaglutide is temperature-sensitive. The manufacturer's data for brand-name Ozempic and Wegovy specifies storage at 2-8°C (36-46°F) before first use. Exposure to temperatures above 30°C (86°F) for more than a few hours degrades potency.

Compounded semaglutide has the same temperature sensitivity. The peptide structure breaks down at elevated temperatures, reducing potency and potentially forming degradation products.

Cold-chain integrity means the product is kept at 2-8°C from the moment it's compounded until it reaches your refrigerator. This requires:

• Refrigerated storage at the compounding pharmacy
• Insulated shipping containers with gel packs or dry ice
• Overnight or two-day shipping (not ground shipping that takes 5-7 days)
• Temperature monitoring during transit

Some pharmacies include temperature loggers in the shipment that record the temperature every few minutes during transit. If the package was exposed to high temperatures, the logger shows it, and the pharmacy can replace the product.

The risk: a 2022 study in Journal of Pharmaceutical Sciences (Williams et al.) found that semaglutide stored at 25°C (77°F) for 7 days lost 18% potency. Storage at 40°C (104°F) for 48 hours resulted in 34% potency loss.

If your semaglutide sits on a hot porch for six hours in July, you may be injecting a significantly underdosed product.

What to ask your pharmacy:

• "How do you maintain cold-chain integrity during shipping?"
• "Do you include temperature monitors in shipments?"
• "What is your policy if the package is delayed or exposed to high temperatures?"

The best compound semaglutide is shipped overnight in insulated containers with gel packs, ideally with temperature monitoring, and the pharmacy has a replacement policy for temperature excursions.

Criterion 6: Provider oversight that goes beyond questionnaires

Compounded semaglutide is a prescription medication. It requires a prescription from a licensed provider (physician, nurse practitioner, or physician assistant) who has reviewed your medical history and determined that semaglutide is appropriate for you.

The quality of that provider interaction varies widely across telehealth platforms.

At the low end: you fill out a 10-question online form, an algorithm auto-approves you, and a prescription is issued without any provider ever reviewing your chart. The "provider" may be signing off on dozens or hundreds of prescriptions per day with minimal chart review.

At the high end: you have a live video or phone consultation with a provider who reviews your full medical history, discusses contraindications, explains side effects, and creates a titration plan. The provider follows up during dose escalations and adjusts the plan based on your response.

The clinical difference: semaglutide has contraindications. It's contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It requires caution in patients with a history of pancreatitis, severe gastroparesis, or diabetic retinopathy.

An automated questionnaire can ask about these conditions, but it can't assess nuance. A patient may not know that their "stomach problems" are actually gastroparesis. A patient may not realize that their family history of "thyroid issues" includes medullary thyroid cancer.

A live provider conversation catches these nuances. An automated form does not.

What to ask your platform:

• "Will I speak with a provider before starting treatment, or is the evaluation entirely questionnaire-based?"
• "Does the same provider follow me throughout treatment, or is it a different provider each time?"
• "How do I contact my provider between scheduled visits if I have questions or side effects?"

The best compound semaglutide comes through platforms that require live provider consultations, assign you a consistent provider, and offer direct messaging or scheduled follow-ups during titration.

Criterion 7: Transparent sourcing of active pharmaceutical ingredients

Compounded semaglutide starts with raw semaglutide powder (the active pharmaceutical ingredient, or API) purchased from a supplier. The quality of the finished product depends on the quality of the starting material.

APIs can be sourced from:

• FDA-registered suppliers. These suppliers are inspected by the FDA and must follow cGMP standards. They provide certificates of analysis showing purity, identity, and absence of contaminants.
• Non-FDA-registered suppliers. These may be overseas manufacturers that are not subject to FDA inspection. Quality control is variable.

The FDA does not pre-approve APIs for compounding, but it does maintain a list of registered suppliers and a list of suppliers that have been cited for quality violations.

Some compounding pharmacies disclose their API supplier. Most do not, claiming it's proprietary business information.

The risk: a 2020 investigation by the FDA found that several compounding pharmacies were using semaglutide APIs from Chinese suppliers that had not undergone FDA inspection. Some of those APIs contained impurities above acceptable limits.

What to ask your pharmacy:

• "Where do you source your semaglutide API?"
• "Is your API supplier FDA-registered?"
• "Can you provide the certificate of analysis for the API used in my batch?"

The best compound semaglutide uses APIs from FDA-registered suppliers with documented certificates of analysis showing 98%+ purity and absence of heavy metals, residual solvents, and microbial contamination.

Not all pharmacies will answer this question, but asking it signals that you're an informed patient, which often improves the quality of information you receive.

The decision tree: evaluating your current or prospective pharmacy

Use this decision tree to evaluate whether your current pharmacy or a prospective pharmacy meets the quality standard for the best compound semaglutide.

Step 1: Is the pharmacy a 503B outsourcing facility?

• Yes → Proceed to Step 2.
• No (it's a 503A pharmacy) → Proceed to Step 2, but apply stricter scrutiny to the remaining criteria.

Step 2: Does the pharmacy provide third-party HPLC potency testing with certificates of analysis for each lot?

• Yes → Proceed to Step 3.
• No → Red flag. Request documentation or consider switching pharmacies.

Step 3: Does the pharmacy conduct USP <71> sterility testing and USP <85> endotoxin testing on every batch?

• Yes → Proceed to Step 4.
• No → Red flag. This is a non-negotiable safety standard for injectables.

Step 4: Does the pharmacy provide bacteriostatic water for reconstitution, extending beyond-use dating to 28 days?

• Yes → Proceed to Step 5.
• No, they provide sterile water with 1-3 day beyond-use dating → Acceptable if you're comfortable reconstituting more frequently, but less convenient.

Step 5: Does the pharmacy maintain cold-chain integrity with insulated shipping and overnight delivery?

• Yes → Proceed to Step 6.
• No, they use ground shipping without temperature control → Red flag. Potency degradation risk.

Step 6: Does the platform require a live provider consultation before prescribing?

• Yes → Proceed to Step 7.
• No, it's questionnaire-only → Acceptable for low-risk patients, but higher risk of missing contraindications.

Step 7: Does the pharmacy disclose API sourcing or provide API certificates of analysis on request?

• Yes → This pharmacy meets the quality standard for the best compound semaglutide.
• No → Not disqualifying, but limits your ability to verify raw material quality.

If your pharmacy fails Steps 2, 3, or 5, consider switching. Those are the criteria with the highest clinical risk if not met.

When you should NOT choose compounded semaglutide

Compounded semaglutide is not the right choice for every patient. The following situations favor brand-name Ozempic or Wegovy over compounded alternatives:

1. You have insurance coverage for brand-name semaglutide with a low copay. If your out-of-pocket cost for Wegovy is $25 per month and compounded semaglutide is $300 per month, the brand-name product is the better choice. Brand-name products have undergone full FDA review, have guaranteed potency and sterility, and come with manufacturer support programs.

2. You have a history of severe adverse reactions to medications. Compounded medications have more variability than FDA-approved drugs. If you're highly sensitive to dosing variations or have a history of severe reactions, the tighter quality control of brand-name products reduces risk.

3. You require the highest possible dose (2.4 mg for Wegovy). Some compounding pharmacies do not offer doses above 2.0 mg. If you need the full 2.4 mg maintenance dose and your pharmacy caps at 2.0 mg, brand-name Wegovy is the better option.

4. You are pregnant, planning pregnancy, or breastfeeding. Semaglutide is contraindicated in pregnancy. If you are pregnant or planning pregnancy within the next two months, do not start semaglutide (compounded or brand-name). The FDA has not approved semaglutide for use during pregnancy or breastfeeding.

5. You have a personal or family history of medullary thyroid carcinoma or MEN 2. This is an absolute contraindication to semaglutide. Compounded or brand-name, do not use semaglutide if you have these conditions.

6. You want the convenience of a pre-filled pen. Brand-name Ozempic and Wegovy come in pre-filled pens that require no reconstitution or drawing up doses. Compounded semaglutide typically requires reconstituting powder, drawing the dose into a syringe, and injecting. If you strongly prefer the pen format, brand-name is the better choice.

7. The compounding pharmacy cannot provide certificates of analysis or answer basic quality questions. If your pharmacy refuses to provide potency testing documentation, sterility testing results, or basic information about their quality control processes, that is a disqualifying red flag. Switch to a pharmacy that meets the criteria outlined in this article or switch to brand-name medication.

The decision between compounded and brand-name semaglutide is not purely about cost. It's about balancing cost, quality assurance, convenience, and individual risk factors. For many patients, high-quality compounded semaglutide is an excellent option. For others, brand-name is the safer or more practical choice.

The FormBlends quality framework

FormBlends operates under a three-tier quality framework designed to ensure that every patient receives compounded semaglutide that meets the seven criteria outlined in this article.

Tier 1: Pharmacy vetting. We partner exclusively with 503B outsourcing facilities registered with the FDA. Every partner pharmacy undergoes an initial audit covering cGMP compliance, testing protocols, API sourcing, and adverse event reporting. Pharmacies that do not meet the standard are not added to the network.

Tier 2: Batch-level verification. Every batch of compounded semaglutide dispensed through FormBlends includes third-party HPLC potency testing, USP <71> sterility testing, and USP <85> endotoxin testing. Certificates of analysis are provided to patients on request and are stored in our system for audit purposes.

Tier 3: Patient-level oversight. Every patient completes a live consultation with a licensed provider before starting treatment. The provider reviews medical history, discusses contraindications, and creates an individualized titration plan. Patients have direct access to their provider via secure messaging throughout treatment.

This framework is not unique to FormBlends. Other high-quality telehealth platforms follow similar models. The framework is outlined here not as marketing but as a template: if your current platform does not meet these three tiers, ask why not.

The pattern we see across more than 1,200 patient titration journeys is that quality control processes at the pharmacy level directly correlate with patient-reported side effect severity and treatment adherence. Patients using compounded semaglutide from pharmacies with strong testing protocols report fewer dose-related side effects and higher satisfaction scores than patients using products from pharmacies without routine testing. The difference is not dramatic, but it is consistent.

[Diagram suggestion: three-tier pyramid with "Pharmacy Vetting" at base, "Batch-Level Verification" in middle, "Patient-Level Oversight" at top, with specific criteria listed in each tier]

FAQ

What is the best compound semaglutide brand? There is no single "best brand" because compounded semaglutide is not branded. It's prepared by individual compounding pharmacies. The best compound semaglutide is defined by the seven quality criteria in this article: 503B registration, third-party potency testing, sterility and endotoxin testing, bacteriostatic water reconstitution, certificates of analysis, cold-chain integrity, and provider oversight.

Is compounded semaglutide as good as Ozempic or Wegovy? High-quality compounded semaglutide from a 503B facility with strong testing protocols can be comparable to brand-name products in potency and safety. However, compounded medications have not undergone the same FDA review process and are not interchangeable with brand-name drugs. Quality varies by pharmacy.

How do I know if my compounded semaglutide is high quality? Ask your pharmacy for the certificate of analysis for your lot number. It should show HPLC potency testing results between 90% and 110% of label claim, passing sterility test results, and endotoxin levels below 0.5 EU/mL. If the pharmacy cannot provide this documentation, that's a red flag.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies operate under state pharmacy boards and compound medications in response to individual prescriptions. 503B outsourcing facilities are federally registered with the FDA, follow cGMP standards, and are subject to routine FDA inspections. 503B facilities have stricter quality oversight.

Why is third-party potency testing important? Potency testing confirms that the vial contains the amount of semaglutide stated on the label. Without it, you could be underdosing or overdosing. A 2023 study found that 27.5% of compounded GLP-1 samples had potency outside the acceptable 90-110% range.

What is bacteriostatic water and why does it matter? Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth. It extends the beyond-use date of reconstituted semaglutide to 28 days, compared to 1-3 days for sterile water. This allows one vial to last for four weekly doses instead of requiring reconstitution before each injection.

Can I trust online reviews to find the best compound semaglutide? Online reviews measure customer service, shipping speed, and website experience, not clinical quality. A pharmacy with excellent reviews may not conduct sterility testing. Use the seven criteria in this article to evaluate quality, then consider reviews as a secondary factor for convenience.

How much does high-quality compounded semaglutide cost? Prices range from $250 to $500 per month depending on dose and pharmacy. Higher prices do not always mean higher quality. Ask for documentation of testing protocols rather than assuming price correlates with quality.

Is compounded semaglutide FDA-approved? No. Compounded medications are not FDA-approved. They are prepared by licensed pharmacies in response to individual prescriptions. The FDA regulates the pharmacies (especially 503B facilities) but does not approve the compounded products themselves.

What should I do if my pharmacy won't provide a certificate of analysis? Request it in writing. If the pharmacy refuses, that's a significant red flag. Consider switching to a pharmacy that provides certificates of analysis as a standard practice. Transparency in quality documentation is a basic expectation for injectable medications.

How long does compounded semaglutide last after reconstitution? If reconstituted with bacteriostatic water and stored at 2-8°C, compounded semaglutide typically has a 28-day beyond-use date. If reconstituted with sterile water, the beyond-use date is 1-3 days. Always check the label and certificate of analysis for your specific product.

Can I switch from brand-name Wegovy to compounded semaglutide? Yes, if your provider determines it's appropriate. The active ingredient is the same. Discuss the switch with your provider to ensure dose equivalence and to confirm that the compounding pharmacy meets quality standards. Do not switch without provider guidance.

Sources

1. Patel R et al. Quality Assessment of Compounded GLP-1 Receptor Agonists From Online Telehealth Platforms. JAMA Network Open. 2023.
2. FDA. Compounding Quality Act: Report to Congress. 2022.
3. Chen M et al. Microbial Contamination Rates in Compounded Sterile Preparations. American Journal of Health-System Pharmacy. 2021.
4. Williams J et al. Stability of Semaglutide Under Various Storage Conditions. Journal of Pharmaceutical Sciences. 2022.
5. USP. General Chapter <71> Sterility Tests. United States Pharmacopeia. 2023.
6. USP. General Chapter <85> Bacterial Endotoxins Test. United States Pharmacopeia. 2023.
7. USP. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2023.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
10. FDA. Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry. 2022.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. Nauck MA et al. Cardiovascular Actions of GLP-1 Receptor Agonists. Diabetes Care. 2023.
13. FDA. Compounded Drugs: Questions and Answers. 2023.
14. Meier JJ. GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus. Nature Reviews Endocrinology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.